SCHEMBL5698339

SCHEMBL5698339

COc1cc(C=O)c(C=O)cc1OC

nearest known ligand 0.81

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.81
KDM4E B2RXH2 2/20 0.81
TSHR P16473 2/20 0.81
TDP1 Q9NUW8 1/20 0.81
PRKDC P78527 2/20 0.71
CYP3A4 P08684 2/20 0.61
MAPT P10636 2/20 0.61
ALOX15 P16050 1/20 0.61
HSD17B10 Q99714 1/20 0.61
ERN1 O75460 6/20 0.52
LMNA P02545 1/20 0.50
HPGD P15428 1/20 0.50
HMGCR P04035 1/20 0.50
TLR2 O60603 1/20 0.48
TLR1 Q15399 1/20 0.48
TLR6 Q9Y2C9 1/20 0.48
NFE2L2 Q16236 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.46
FDPS P14324 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Asaraldehyde SCHEMBL29456596 0.90 ALDH1A1 (1.00) ALDH1A1KDM4ETSHRTDP1PRKDC
Asaraldehyde SCHEMBL333451 0.90 ALDH1A1 (1.00) ALDH1A1KDM4ETSHRTDP1PRKDC
SCHEMBL3136850 0.89 ALDH1A1 (0.90) ALDH1A1KDM4ETSHRTDP1PRKDC
Asaraldehyde SCHEMBL27489564 0.87 ALDH1A1 (0.95) ALDH1A1KDM4ETSHRTDP1PRKDC
SCHEMBL18232228 0.85 ALDH1A1 (0.61) ALDH1A1KDM4ETSHRTDP1PRKDC
SCHEMBL1494078 0.85 ALDH1A1 (0.68) ALDH1A1KDM4ETSHRTDP1PRKDC
SCHEMBL71268 0.84 ALDH1A1 (0.65) ALDH1A1KDM4ETSHRTDP1PRKDC
SCHEMBL13537963 0.84 ALDH1A1 (0.65) ALDH1A1KDM4ETSHRTDP1PRKDC
SCHEMBL1589608 0.84 ALDH1A1 (0.65) ALDH1A1KDM4ETSHRTDP1PRKDC
SCHEMBL1570740 0.84 ALDH1A1 (0.72) ALDH1A1KDM4ETSHRTDP1PRKDC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1501471-B1 USE OF ALPHA-DIALDEHYDES IN THE PRESENCE OF AN AMMONIUM SALT OF A BRÖNSTED ACID FOR DYEING KERATIN FIBRES OREAL (FR) 2006-06-07 EP claimed
US-20050273946-A1 Use of alpha-dialdehydes in the presence of an ammonium salt of a bronsted acid for dyeing keratin fibres L'OREAL S.A. (FR) 2005-12-15 US claimed
EP-1501471-A1 USE OF ALPHA-DIALDEHYDES IN THE PRESENCE OF AN AMMONIUM SALT OF A BRÖNSTED ACID FOR DYEING KERATIN FIBRES L'OREAL (FR) 2005-02-02 EP claimed
US-20040205905-A1 Dye composition for keratin fibers, comprising at least one compound chosen from ortho- and alpha-dialdehyde compounds and at least one sulphur compound L'OREAL S.A. (FR) 2004-10-21 US claimed
EP-1430878-A1 Composition to dye keratinic fibres comprising at least one ortho- or alpha-dialdehyde and at least one sulphurous compound L'OREAL (FR) 2004-06-23 EP claimed
WO-2003090701-A1 USE OF α-DIALDEHYDES IN THE PRESENCE OF AN AMMONIUM SALT OF A BRÖNSTED ACID FOR DYEING KERATIN FIBRES L'OREAL (FR) 2003-11-06 WO claimed
US-20240400575-A1 POLYCYCLIC COMPOUNDS AS SOLUBLE EPOXIDE HYDROLASE INHIBITORS UNIV BARCELONA (ES) 2024-12-05 US disclosed
EP-3810572-B1 POLYCYCLIC COMPOUNDS AS SOLUBLE EPOXIDE HYDROLASE INHIBITORS UNIV BARCELONA (ES) 2023-11-15 EP disclosed
CN-112888674-B Polycyclic compounds as soluble epoxide hydrolase inhibitors 巴塞罗那大学 2023-06-30 CN disclosed
US-20210289794-A1 COMPOSITIONS AND RELATED METHODS FOR AGRICULTURE FLAGSHIP PIONEERING INNOVATIONS V, INC. 2021-09-23 US disclosed
CN-112888674-A Polycyclic compounds as soluble epoxide hydrolase inhibitors 巴塞罗那大学 2021-06-01 CN disclosed
US-11008282-B2 Bicyclic-compounds for use as a medicament, in particular for treatment of parkinson's disease KOESTER HUBERT (CH) 2021-05-18 US disclosed
EP-3810572-A1 POLYCYCLIC COMPOUNDS AS SOLUBLE EPOXIDE HYDROLASE INHIBITORS Universitat de Barcelona (ES) 2021-04-28 EP disclosed
EP-1501471-B1 USE OF ALPHA-DIALDEHYDES IN THE PRESENCE OF AN AMMONIUM SALT OF A BRÖNSTED ACID FOR DYEING KERATIN FIBRES OREAL (FR) 2006-06-07 EP disclosed
US-20050273946-A1 Use of alpha-dialdehydes in the presence of an ammonium salt of a bronsted acid for dyeing keratin fibres L'OREAL S.A. (FR) 2005-12-15 US disclosed
EP-1501471-A1 USE OF ALPHA-DIALDEHYDES IN THE PRESENCE OF AN AMMONIUM SALT OF A BRÖNSTED ACID FOR DYEING KERATIN FIBRES L'OREAL (FR) 2005-02-02 EP disclosed
US-20040205905-A1 Dye composition for keratin fibers, comprising at least one compound chosen from ortho- and alpha-dialdehyde compounds and at least one sulphur compound L'OREAL S.A. (FR) 2004-10-21 US disclosed
EP-1430878-A1 Composition to dye keratinic fibres comprising at least one ortho- or alpha-dialdehyde and at least one sulphurous compound L'OREAL (FR) 2004-06-23 EP disclosed
WO-2003090701-A1 USE OF α-DIALDEHYDES IN THE PRESENCE OF AN AMMONIUM SALT OF A BRÖNSTED ACID FOR DYEING KERATIN FIBRES L'OREAL (FR) 2003-11-06 WO disclosed
US-4017313-A Photosensitive composition containing a leuco dye, a photosensitizer, an aromatic aldehyde and a secondary or tertiary amine and the use thereof in a direct-print process E. I. DU PONT DE NEMOURS AND COMPANY (US) 1977-04-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050273946-A1 Use of alpha-dialdehydes in the presence of an ammonium salt of a bronsted acid for dyeing keratin fibres KRT18, PDIA5, CA6 ALDH1A1 341/4885KDM4E 4170/4885TSHR 3743/4885
US-20040205905-A1 Dye composition for keratin fibers, comprising at least one compound chosen from ortho- and alpha-dialdehyde compounds and at least one sulphur compound KRT18, DSP, DSG1 ALDH1A1 50/4885KDM4E 1902/4885TSHR 4023/4885
US-11008282-B2 Bicyclic-compounds for use as a medicament, in particular for treatment of parkinson's disease COMT, PNMT, DBH ALDH1A1 576/4885KDM4E 2139/4885TSHR 1069/4885
US-20240400575-A1 POLYCYCLIC COMPOUNDS AS SOLUBLE EPOXIDE HYDROLASE INHIBITORS EPHX1, EPHX2, NCEH1 ALDH1A1 81/4885KDM4E 2361/4885TSHR 4075/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.